TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Proficient in English, assessed with items asking about native language and self-reported comfort communicating in English among non-native speakers.~* Age ≥18 years old, assessed by self-report and verified by date of birth.~* Has smoked ≥100 cigarettes and currently smokes ≥5 cigarettes per day, verified by an exhaled carbon monoxide level of ≥8 ppm.~* Ready to try quitting smoking within the next month.~* Currently homeless, assessed by self-report and defined as usually staying in an emergency shelter, transitional shelter, abandoned building, place of business, car or other vehicle, church or mission, hotel or motel, or anywhere outside during the past 7 days. Additionally, individuals will be considered currently homeless if they usually stayed in somebody else's house, apartment/condominium, or room in the past 7 days because of not having their own place to stay.~Exclusion Criteria:~* Currently pregnant, assessed by a urine pregnancy test conducted on all premenopausal biologic females who have not had a hysterectomy, or planning to become pregnant in the next 2 months.~* Past 30-day use of nicotine replacement therapy, bupropion, or varenicline for smoking cessation, assessed by self-report. Use of bupropion for reasons other than to quit smoking (e.g. depression) is permissible.~* Prior serious adverse reaction to the nicotine patch, defined as any reaction that was life-threatening or required hospitalization.~* Heart attack or chest pain within the past 2 weeks.~* Inability to read a sentence written at a Flesch-Kincaid grade level of 4.~* Inability to provide informed consent, assessed with knowledge questions about the material presented during the informed consent process that individuals must correctly answer before providing informed consent to participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (N=25) (Type: ACTIVE_COMPARATOR): * Transdermal nicotine patch~* In-person smoking cessation counseling
- Financial rewards (N=25) (Type: EXPERIMENTAL): * Transdermal nicotine patch~* In-person smoking cessation counseling~* Contingent financial rewards for smoking abstinence
- Text messaging (N=25) (Type: EXPERIMENTAL): * Transdermal nicotine patch~* In-person smoking cessation counseling~* Text messages to support smoking abstinence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ≥ 18 years at the time of signing informed consent.~* Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis.~* Must have had at least 1 but no greater than 3 prior anti-myeloma regimens.~* Must have documented disease progression during or after their last anti-myeloma therapy.~* All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.~Exclusion Criteria:~* Documented progressive disease during therapy or within 60 days of the last dose of a bortezomib-containing therapy under the 1.3 mg/m\^2 dose twice weekly dosing schedule.~* Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization.~* Non-secretory multiple myeloma.~* Subjects with severe renal impairment requiring dialysis.~* Previous therapy with pomalidomide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide, Bortezomib and Low Dose Dexamethasone (Type: EXPERIMENTAL): 4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
- Bortezomib and Low Dose Dexamethasone (Type: ACTIVE_COMPARATOR): 1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Against Anthracycline-induced Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \>50%~* first diagnosed breast cancer~* female sex~Exclusion Criteria:~* Prior breast cancer and/or prior anthracycline exposure history~* LVEF \<50%~* Use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and beta blockers~* Creatinin value \>2 mg/dl~* Presence of chronic kidney failure~* Potassium value \>5.3 mg/dl~* Presence of adrenal gland diseases,~* Presence of severe liver failure~* Co-morbidities such as coronary heart disease, hypertension, atrial fibrillation, and valvular heart disease.~* Male patients were excluded for the homogenization of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: ACTIVE_COMPARATOR): patients who randomized to spironolactone administered arm
- Placebo (Type: PLACEBO_COMPARATOR): Patients who randomized to placebo administered arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Inpatients meet the DSM-IV criteria for schizophrenia.~2. Treatment refractoriness: Failed to respond to at least two typical neuroleptics at dosage equivalent to or greater than 1000 mg/day of chlorpromazine for a period of at least six weeks.~3. Age 18-60 years.~4. Males or females.~5. Total PANSS score \>60~6. Good physical health determined by complete physical examination, laboratory tests, and EKG.~7. Capacity and willingness to give written informed consent.~Exclusion Criteria:~1. History of illicit substance abuse or dependence~2. History of clozapine intolerance (such as clinically significant leukopenia or agranulocytosis).~3. Patients with WBC count less than 3500/mm3 or ANC count less than 2000/mm3will not be included.~4. Any depot neuroleptics within 30 days before the day of randomization.~5. Epilepsy, active hepatitis, HIV positivity, or current myeloproliferative disorder. Other medical illnesses may necessitate subjects' exclusion after evaluation of individual cases by the principal investigator and other staffs. Clinical judgment will be used.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- clozapine + fluvoxamine (Type: ACTIVE_COMPARATOR): None
- clozapine + placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Insomnia Secondary to Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 35-75~* Chronic non-malignant painful condition of the spine of \> 6 months duration~* Insomnia (\> 30 minutes sleep latency and/or wake after sleep onset time for \> 3 days/week for \> 6 months)~* Insomnia developed after the onset of the painful condition~* Preferred sleep phase between 10:00 p.m. and 8:00 am~* On stable medical regimen for medical and pain conditions (no surgery planned)~* Willingness to discontinue hypnotic medications~Exclusion Criteria:~* Unstable medical or psychiatric illness~* History of seizures~* Evidence of active illicit substance use or fitting criteria for ethanol (ETOH) abuse or dependence~* Symptoms suggestive of sleep disorders other than insomnia~* Polysomnographic data indicating sleep disorders other than insomnia~* Inadequate language comprehension~* Fibromyalgia~* Pregnancy

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CBT for Insomnia (CBT-I) (Type: ACTIVE_COMPARATOR): Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
- CBT for Pain (CBT-P) (Type: ACTIVE_COMPARATOR): Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
- CBT for Insomnia & Pain (CBT-I/P) (Type: EXPERIMENTAL): Combined Cognitive-Behavioral Therapy for Insomnia \& Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
- Wait-List Control (WL) (Type: NO_INTERVENTION): Waitlist Control condition (WL) with no contact during the intervention period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A prior confirmed positive test for COVID19 and lingering symptoms are required for inclusion.~As outlined on the CDC website, lingering symptoms include:~* Tiredness or fatigue~* Difficulty thinking or concentrating (sometimes referred to as brain fog)~* Headache~* Loss of smell or taste~* Dizziness on standing~* Fast-beating or pounding heart (also known as heart palpitations)~* Chest pain~* Difficulty breathing or shortness of breath~* Cough~* Joint or muscle pain~* Depression or anxiety~* Fever~* Symptoms that get worse after physical or mental activities~Exclusion Criteria:~* Viral infections other than COVID-19.~* Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina~* Pregnancy~* Females of childbearing potential age not on adequate contraception or lactating~* Subjects receiving systemic corticosteroid treatment within one month of Screening Visit~* Subjects Less than 18 years of age~* Hospitalization within last 6 months due to acute exacerbation of airway disease~* Subjects with a clinically significant abnormal chest x-ray within past 12 months~* Medication changes within one month of study entry~* Subjects who have participated in another investigation drug treatment study within the previous month.~* Subjects with a current history of alcohol or recreational drug abuse.~* Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray (Type: EXPERIMENTAL): This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Long-Term Infliximab for Psoriasis (P05319)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant must have a diagnosis of plaque-type psoriasis~* Participant's physician must have decided, with the subject's consent, to start treatment with infliximab~* Participant must demonstrate willingness to participate in the study and agree with the procedures of the study by signing the written informed consent~* For inclusion into the extended treatment period, participant must have completed 50 weeks of infliximab treatment in the treatment period~* For inclusion into the extended treatment period, participant must be continuing treatment with intravenous infliximab~* For inclusion into the extended treatment period, participant must have an improvement in their PASI score of greater than or equal to 25% at the time of entry into to the extended treatment period~Exclusion Criteria:~For the Treatment Period~* Given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is eligible for the trial (Inclusion Criteria). The treating physician is expected, as in normal clinical practice, to follow the PM (Canada), the approved SPC (EU), or local labeling (for all other participating countries) regarding contraindications and precautions~For the Extended Treatment Period~* Given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is receiving infliximab treatment in accordance with the PM (Canada), the approved SPC (EU), or local labeling (for all other participating countries) regarding contraindications, precautions, dosing and frequency of administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab 5 mg/kg (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) infection~* Japanese Male and female patients aged 18 years or above~* Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection, with/without SSTI (skin and soft tissue infection)-derived MRSA bacteremia suspected~Exclusion Criteria:~* Having received any systemic antibacterial potentially effective against MRSA for \>/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for \>/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA.~* Moribund clinical condition such as death likely within the first 3 days of a study drug treatment~* History of significant allergy or intolerance to linezolid or BAY1192631~* Known or suspected human immunodeficiency virus (HIV) infection with a CD4+ T-cell count \< 200/μL~* Chronic treatment with immunosuppressive drugs~* Active tuberculosis or non-tuberculous mycobacteriosis which need medical treatments~* Current or anticipated neutropenia with neutrophil count \< 1,000/ mm\^3~* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with Child Pugh score \>/=10.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tedizolid Phosphate (Sivextro, BAY1192631) (Type: EXPERIMENTAL): Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
- Linezolid (Type: ACTIVE_COMPARATOR): Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: APL93: Timing of CxT and Role of Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of APL, based on morphology criteria~2. Age 75 years or less; and~3. Written informed consent. Diagnosis had to be subsequently confirmed by presence of t(15;17) or PML-RAR gene rearrangement. In the absence of t(15;17) and if no analysis of the rearrangement could be made, review of initial marrow slides by an independent morphologist was mandatory.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATRA ->Chemo (Type: NO_INTERVENTION): Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
- ATRA+CT (Type: EXPERIMENTAL): Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
- High WBC (Type: NO_INTERVENTION): Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA-\>CT group (elderly group), respectively.
- no maintenance (Type: NO_INTERVENTION): No maintenance
- maintenance ATRA (Type: EXPERIMENTAL): Intermitent ATRA as maintenance
- maintenance Cxt (Type: EXPERIMENTAL): continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
- maintenance both (Type: EXPERIMENTAL): continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with impaired glucose tolerance (2 h glucose between 140 - 199 mg / dL) that after 1 year of treatment with metformin at a dose of 1700 mg daily + lifestyle modifications don't achieve normoglycemia.~* Patients who accept to participate in the study and sign informed consent.~Exclusion Criteria:~* Patients with type 2 Diabetes diagnosted previuosly or detected during the OGTT~* Serum creatinine \> 1.6 mg/dL~* Hypertriglyceridemia very high (\>500 mg/dL)~* Pregnancy~* Systolic blood pressure \> 180 mmHg or Diastolic blood pressure \>105 mmHg (patients could be re-screened after blood pressure control)~* Excessive alcohol intake, acute or chronic~* Medications or medical conditions that affect glucose homeostasis (thiazides, beta blockers, glucocorticoids for systemic use, weight-reducing drugs or anorexigenics, Cushing's syndrom, Thyrotoxicosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin + Metformin and lifestyle (Type: EXPERIMENTAL): Patients with impaired glucose tolerance randomly assigned to linagliptin 2.5 mg + metftormin 850 mg every 12 hours during 6 months.
- Metformin (Type: ACTIVE_COMPARATOR): Patients with impaired glucose tolerance randomly assigned to metftormin 850 mg every 12 hours during 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BAY43-9006 Phase II Study for Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who suffer from unresectable and/or metastatic, measurable RCC histologically or cytologically documented.~* Patients with rare subtypes of RCC, such as pure papillary cell tumor, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors, are excluded from study participation.~Exclusion Criteria:~* More than three regimens of previous treatment for RCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete